Orabase Baby Teething Gel (benzocaine formulation) Disease Interactions
There is 1 disease interaction with Orabase Baby Teething Gel (benzocaine formulation) (benzocaine topical).
Benzocaine (applies to Orabase Baby Teething Gel (benzocaine formulation)) methemoglobinemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: G-6-PD Deficiency
Rarely, benzocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis. Therapy with benzocaine should be administered cautiously to patients with or predisposed to methemoglobinemia. If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition except in G-6-PD-deficient patients.
Switch to professional interaction data
Orabase Baby Teething Gel (benzocaine formulation) drug interactions
There are 55 drug interactions with Orabase Baby Teething Gel (benzocaine formulation) (benzocaine topical).
Report options
More about Orabase Baby Teething Gel (benzocaine formulation) (benzocaine topical)
- Check interactions
- Compare alternatives
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- Drug class: topical anesthetics
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.